The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
Open accessAbstract
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies on selective degradation of pathogenic proteins via small chimeric molecules linking an E3 ubiquitin ligase to the targeted protein for proteasomal degradation. To this end, we recently developed a protein knockdown system based on hybrid small molecule SNIPERs (Specific and Nongenetic IAP-dependent Protein Erasers) that recruit inhibitor of the apoptosis protein (IAP) ubiquitin ligases to specifically degrade targeted proteins. Here, we extend our previous study to show a proof of concept of the SNIPER technology in vivo . By incorporating a high affinity IAP ligand, we developed a novel SNIPER against estrogen receptor α (ERα), SNIPER(ER)-87, that has a potent protein knockdown activity. The SNIPER(ER) reduced ERα levels in tumor xenografts and suppressed the growth of ERα-positive breast tumors in mice. Mechanistically, it preferentially recruits X-linked IAP (XIAP) rather than cellular IAP1, to degrade ERα via the ubiquitin-proteasome pathway. With this IAP ligand, potent SNIPERs against other pathogenic proteins, BCR-ABL, bromodomain-containing protein 4 (BRD4), and phosphodiesterase-4 (PDE4) could also be developed. These results indicate that forced ubiquitylation by SNIPERs is a useful method to achieve efficient protein knockdown with potential therapeutic activities and could also be applied to study the role of ubiquitylation in many cellular processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using this new approach, the authors demonstrated robust degradation of ERα, the chronic myeloid leukemia (CML)-causative BCR–Abl fusion protein, BRD4 and PDE4 proteins in cells [102].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [102]
In the citing paper
“Next-generation PROTACs later derived from more potent peptido-mimetic ligands of IAPs were shown to efficiently induce the knockdown of diverse proteins such as ERα, BCR-ABL, BRD4 or PDE4 (ref. 122 ).”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [122]
In the citing paper
“Inhibitor of apoptosis (IAP) E3 ligases feature a baculoviral IAP repeat (BIR) domain”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [122]
In the citing paper
“that can be exploited for proteolysis targeting chimera (PROTAC) discovery 122 .”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2559 · Cited by 2,648
IAP family proteins---suppressors of apoptosisPreprint
Deveraux, Q. L., & Reed, J. C. (1999) · Genes & Development · doi:10.1101/gad.13.3.239 · Cited by 2,535
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 2,002
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,956
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Flagged first, then by citations
2 of the 42 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–248 of 248
Targeted Management: Unlocking the Crucial Role of PROTACs in Cancer Treatment
Gupta, P., Dutta, S., Kumar, P., Kaushik, M., Ashique, S., & Bhowmick, M. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638324854250218053353 · Cited by 5
A PDE4 shortform degrader: a first in isoform‐specific PDE4 inhibition
Maurice, D. H. (2025) · FEBS Journal · doi:10.1111/febs.70059 · Cited by 4
Yang, J., Wang, Q.-L., Feng, G., & Zeng, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900210 · Cited by 4
Expanding the toolbox to develop IAP-based degraders of TEAD transcription factors
Gupta, N., Trainor, N. B., Radwan, M., Nguyen, S., Duncan, L. J., Tang, A. X., Beveridge, J. G., Silke, N., Yousef, J. M., Bilgilier, C., et al. (2026) · Communications Chemistry · doi:10.1038/s42004-025-01871-x · Cited by 3
Fulfilling multiple roles in PROTAC design: The emerging potential of oligonucleotides
Rodrigues, D. A., Pires, G. S., Roy, U., Conway, E., & Pinheiro, P. D. S. M. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118688 · Cited by 3
Ohoka, N., Yokoo, H., Okuhira, K., Demizu, Y., & Naito, M. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1920-9_20 · Cited by 3
Self-citationShakya, A., Liu, Q., Lai, C., Baker, S., Greene, S., Erdman, P. E., Rathnayake, A. D., Schoolmeesters, A., Blair, C. M., Kyurkchieva, E., et al. (2025) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2025.100329 · Cited by 3
Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development
Cooper, M. S., Norley, M. C., Armitage, S., Cresser-Brown, J. O., Edmonds, A. K., Goggins, S., Hopewell, J. P., Karadogan, B., Knights, K. A., Nash, T. J., et al. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob00983a · Cited by 2
Du, W. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2022-0147 · Cited by 2
Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects
Tsukumo, Y., Tsuji, G., Yokoo, H., Shibata, N., Ohoka, N., Demizu, Y., & Naito, M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_18 · Cited by 2
Self-citationTargeted Protein Degradation by Proteolysis Targeting Chimeras
Du, W. (2022) · Wiley eBooks · doi:10.1002/9781119627784.ch11 · Cited by 2
Insights and Future Perspectives of Covalent Protein Degraders
Zhang, X. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch8 · Cited by 2
Cho, N., & Naito, M. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.09.001 · Cited by 1
Self-citationHuang, W., Mao, T.-Y., Dai, G.-Y., Ye, J.-M., Li, J.-B., Chen, S.-B., Tan, J., Huang, Z., & Huang, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00726g · Cited by 1
Context matters in PROTAC design: navigating the trade-off between degradation and developability
Zhang, B., Zhang, Y., Zhang, B., Hu, J., Ke, C., Wu, T., Wei, M., Xia, J., Wang, M., Zhao, Q., et al. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2707656 · Cited by 1
Targeted Protein Degradation Chemical Probes
Galdeano, C., & Barril, X. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00150 · Cited by 1
Hussain, M., Tejeda, G. S., & Baillie, G. S. (2025) · FEBS Journal · doi:10.1111/febs.70205 · Cited by 1
Targeted Protein Degradation – The Story So Far
O’Donovan, D. H., Luh, L. M., & Cromm, P. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch1 · Cited by 1
Identification of clofibric acid as a SYVN1 ligand for PROTAC developmentPreprint
Warren, J., Munakala, A., Zientek, K. D., Kim, K., Wilmarth, P. A., Reddy, A. P., Li, B. X., & Xiao, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.26.701774 · Cited by 1
Degradation of Disease Related Proteins in Living Cells by Small Molecules
Ishikawa, M., & Hashimoto, Y. (2020) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.78.402
Middle Molecular and Conjugation Strategies for Development of Bioactive Middle Molecules
Manabe, Y., Shimoyama, A., Kabayama, K., & Fukase, K. (2020) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.78.527
Chemical Degradation of Disease-related Proteins: Discovery and Challenge for Drug Discovery
Ishikawa, M. (2020) · Drug Delivery System · doi:10.2745/dds.35.229
Intermolecular interaction-based ubiquitin-proteasome system-targeting drug discovery
Naito, M., & Komatsu, H. (2020) · Folia Pharmacologica Japonica · doi:10.1254/fpj.20070
Self-citationCancer Targets Involving the Ubiquitin Proteasome System
Araujo, E. M. V. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc282
Lowe, J. A., III (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739908982.793584562
Hoppe, T. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.731966527.793570381
Structural Considerations and Chemistry of PROTACs
Wahi, A., Jadhav, H. R., Thakur, S., Dev, S., Mohanty, P., & Jain, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_3
Recent aspects in the molecular genetics of Huntington's disease
Mostafa, O. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00022-1
Inhibitors and degraders of epigenetic regulation in cancer
Gao, P., Kanıskan, H. Ü., & Jin, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00037-6
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Targeting the Ubiquitin-Proteasome System in cancer
Spallek, R., McLaughlin, C., & Sapkota, G. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00078-9
Targeted cancer therapy: A comprehensive review of strategies in drug development
Wang, Y., & Tang, S.-C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105303 · Cited by 1
Ma, X., Vaillant, F., Deepagan, V. G., Schoffer, K. L., Rezazadeh‐Shojaee, F., Pang, J., Baldwin, C. A., Murphy, J. M., Silke, J., Tanzer, M. C., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.03.005
Targeting BCL ‐ xL in Myeloid Malignancies: From Inhibitors to PROTAC
Cilloni, D., Ferrando, A., & Frassoni, F. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71036
Warren, J., Munakala, A., Zientek, K. D., Kim, K., Wilmarth, P. A., Reddy, A. P., Li, B. X., & Xiao, X. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00223 · Cited by 1
Zorn, A., Pediani, J. D., Hussain, M., Ling, J., Brown, E., Belka, I., Torres, E., Swindlehurst, C., Chan, K. W. H., Stirling, D., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70528
BindingDB (2025) · UC San Diego · doi:10.7270/q2b85dsn
BindingDB Entry 50018757: PROTACs: New method to degrade transcription regulating proteins.
BindingDB (2024) · UC San Diego · doi:10.7270/q2280cvr
BindingDB Entry 50019734: Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates.
BindingDB (2024) · UC San Diego · doi:10.7270/q2pg1x3j
BindingDB (2024) · UC San Diego · doi:10.7270/q2x352pq
BindingDB Entry 50016327: Selectivity through Targeted Protein Degradation (TPD).
BindingDB (2023) · UC San Diego · doi:10.7270/q22n568r
BindingDB (2024) · UC San Diego · doi:10.7270/q2pv6qt5
Metadata
- Authors
- Ohoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., Fujita, H., Teratani, M., Matsumoto, H., Imaeda, Y., Nara, H., Cho, N., & Naito, M.
- Affiliations
- National Institute of Health Sciences (JP)
- Takeda (Japan) (JP)
- Corresponding author
- Naito, Mikihiko
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 292
- Issue
- 11
- Pages
- 4556-4570
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC5377772
- OpenAlex
- W2585495993
- Cited by
- 240
- References
- 42
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 26 · 2023: 21 · 2022: 36 · 2021: 28 · 2020: 41 · 2019: 28 · 2018: 14 · 2017: 18
- FWCI
- 11.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (publishedVersion, cc-by)
- Funders
- Japan Society for the Promotion of Science (26860049, 16H05090, 16K15121)
- Japan Agency for Medical Research and Development (15ak0101029h1402, 16ak0101029j1403, 16cm0106124j0001)
- Takeda Science Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- snipers, protein degradation, inhibitor of apoptosis proteins, XIAP, estrogen receptor alpha, breast cancer, tumor xenografts, ubiquitin-proteasome system, E3 ubiquitin ligase, BCR-ABL, BRD4, phosphodiesterase 4, protein knockdown, targeted protein degradation
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Line, Female, Humans, Ligands, Mice, Inbred BALB C, Mice, Nude, Cell Line, Tumor, Proteasome Endopeptidase Complex, Estrogen Receptor alpha, Inhibitor of Apoptosis Proteins, Mice, X-Linked Inhibitor of Apoptosis Protein, Small Molecule Libraries, Ubiquitination, Drug Discovery, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
